Want to see TSE:ASTI full AI Analyst Report?
Top Page
Aquarius Surgical Technologies
(ASTI)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$0.02
▼(-25.00% Downside)
Action:Reiterated
Date:08/30/26
The score is primarily held down by very weak financial performance (large losses, negative equity, and ongoing cash burn indicating elevated solvency and funding risk). Technicals are a relative positive with the price trading above key moving averages and positive MACD, but valuation is limited by lack of profitability and no dividend support.
Positive Factors
Revenue Rebound
The TTM revenue rebound shows some renewed demand or commercial traction. Sustaining this growth could improve operating leverage over time, although the company must convert sales into gross profit and eventually reduce its substantial cost burden.
Negative Factors
Negative Equity and High Leverage
Negative equity and debt exceeding the asset base indicate a structurally stressed capital structure. This limits financial flexibility and increases reliance on refinancing, restructuring, or equity issuance that could dilute existing holders.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Rebound
The TTM revenue rebound shows some renewed demand or commercial traction. Sustaining this growth could improve operating leverage over time, although the company must convert sales into gross profit and eventually reduce its substantial cost burden.
Read all positive factors
Aquarius Surgical Technologies (ASTI) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$413.99K
Dividend YieldN/A
Average Volume (3M)7.87K
Price to Earnings (P/E)―
Beta (1Y)0.10
Revenue Growth8.66%
EPS Growth-545.88%
CountryCA
Employees3
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.05
Shares Outstanding27,599,173
10 Day Avg. Volume0
30 Day Avg. Volume7,869
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.06
Price to Sales (P/S)4.53
P/FCF Ratio-3.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aquarius Surgical Technologies Business Overview & Revenue Model
Company Description
Aquarius Surgical Technologies Inc., operating through its subsidiary Surgical Lasers Inc., specializes in the creation, sale, distribution, and promotion of advanced technological solutions tailored for surgical and other healthcare settings thro...
Aquarius Surgical Technologies Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
20
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2023 | Mar 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 91.44K | 91.20K | 203.73K | 583.44K | 958.74K |
| Gross Profit | 33.48K | 47.31K | 81.91K | 216.59K | 378.25K |
| EBITDA | -241.88K | -832.81K | -517.35K | -1.34M | -1.18M |
| Net Income | -651.71K | -1.17M | -723.44K | -1.81M | -1.61M |
Balance Sheet | |||||
| Total Assets | 1.91M | 1.95M | 680.14K | 946.13K | 1.66M |
| Cash, Cash Equivalents and Short-Term Investments | 44.51K | 7.56K | 122.02K | 145.97K | 105.19K |
| Total Debt | 6.94M | 6.47M | 3.51M | 2.93M | 2.02M |
| Total Liabilities | 8.34M | 7.72M | 4.53M | 3.34M | 2.35M |
| Stockholders Equity | -6.42M | -5.77M | -3.85M | -2.39M | -689.15K |
Cash Flow | |||||
| Free Cash Flow | -116.36K | -383.29K | 38.82K | -509.00K | -1.07M |
| Operating Cash Flow | -116.36K | -383.29K | 38.82K | -450.52K | -951.17K |
| Investing Cash Flow | 0.00 | -1.80M | 0.00 | -100.00K | -86.99K |
| Financing Cash Flow | 153.31K | 2.08M | -75.00K | 591.30K | 1.02M |
Aquarius Surgical Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$45.26M | -2.34 | -303.05% | ― | 35.27% | 58.34% | |
48 Neutral | C$12.10M | -7.04 | -34.32% | ― | -5.42% | -5.37% | |
48 Neutral | C$340.12M | -6.11 | -62.45% | ― | 59.60% | 32.53% | |
46 Neutral | C$413.99K | -0.27 | 23.95% | ― | 8.66% | -545.88% | |
43 Neutral | C$18.32M | -4.87 | 78.25% | ― | 89.06% | 37.62% |
* Healthcare Sector Average
TSE:ASTI
Aquarius Surgical Technologies
0.02
<0.01
50.00%
TSE:ASG
Aurora Spine
0.15
-0.13
-46.43%
TSE:PINK
Perimeter Medical Imaging AI
0.30
0.07
34.09%
TSE:PRN
Profound Medical
8.20
2.70
49.09%
TSE:VPT
VentriPoint Diagnostics
0.10
>-0.01
-9.52%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.